Managed Care Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hemispherx Biopharma, Inc.
Ampligen enhances the effectiveness of Tamiflu against Avian influenza
October 9th, 2005
Hemispherx Biopharma, Inc., (HEB) reported two new preclinical studies on double-stranded RNA (dsRNA), including Ampligen, one of its flagship experimental immunomodulators. Both preclinical studies suggest a new, and potentially pivotal, role of dsRNA therapeutics in improving the efficacy of the present standards of care in both influenza prevention and treatment of acute disease. The first preclinical report, conducted by research affiliates of the National Institutes of Health at Utah State University, compared the relative protection conveyed by Tamiflu (oseltamivir, Roche) and Ampligen (dsRNA, Hemispherx), alone and in combination against the...
Source: Managed Care Law Weekly (2005-10-09)
|
